The global market for sepsis diagnostics is also projected to bring in US$ 707.3 million revenue by 2026 end
Rockville Pike, MD -- (SBWIRE) -- 06/28/2019 -- An insightful study, titled "Sepsis Diagnostics Market" has been freshly broadcasted to the vast research repository of FACT.MR. This research study provides detailed comprehensions and forecasts future growth of the global market with an in-depth study of the factors impacting revenue growth throughout the mentioned forecast period. Further, a deep analysis on the major players from diverse regions is also present in the report.
Ask for Free Sample Report at – https://www.factmr.com/connectus/sample?flag=S&rep_id=391
Sepsis is emerging as one of the leading causes of mortality around the globe. However, early detection can improve the outcomes, hence the demand for sepsis diagnostics is also rising. Major companies in the market are also focusing on introducing technically advanced tools and techniques to provide sepsis diagnosis at an early stage. Companies are also entering into mergers and acquisitions to carry research and development activity and expand globally. New products are also being launched, while some products have already received the U.S. Food and Drugs Administration (FDA) clearance to be used for diagnosis purpose. According to the new research by Fact.MR, the global sepsis diagnostics market is likely to grow at a faster phase between 2017 and 2026. The global market for sepsis diagnostics is also projected to bring in US$ 707.3 million revenue by 2026 end.
Conventional Diagnostics to be the Most-Preferred diagnostic Method
Compared to the automated diagnostics, conventional diagnostics is likely to emerge as the most-preferred sepsis diagnosis method. Towards 2026 end, conventional diagnostics is projected to generate more than US$ 400 million revenue. Conventional methods for diagnosis of sepsis is still the most-preferred one due to the low cost and it also leads to the timely changes to appropriate therapy.
Assays & Reagents to Emerge as the Top-Selling Product
Among various products in sepsis diagnostics market, assays & reagents are likely to emerge as the top-selling products. Assays & reagents are projected to surpass US$ 300 million revenue by end of the forecast period. Reagents and assays kits are showing lucrative growth due to the introduction of technically advanced tests by key players. Moreover, assays and reagents facilitate early diagnosis of sepsis.
Gram-positive Bacterial Sepsis to Hold the Largest Share on Basis of Pathogens Causing Septicemia
Gram-positive bacterial sepsis segment is likely to account for the maximum share in terms of revenue in the global market for sepsis diagnostics. Gram-positive bacterial sepsis are projected to reach close to US$ 300 million revenue by 2026 end. Although bacteria causes sepsis on a large scale, the increase in sepsis is due to the gram-positive sepsis. Various studies carried on sepsis are showing that gram-positive bacteria accounts for maximum septic shock and severe sepsis cases. Moreover, the mortality rate due to gram-positive infection is high as compared to the gram-negative infection. Hence, therapeutic protocols are being undertaken to manage both gram-positive and gram-negative sepsis.
Read Detailed Index of full Research Study at @ https://www.factmr.com/report/391/sepsis-diagnostics-market
Microbiology Technology to Witness Attractive Growth between 2017 and 2026
Compared to the various technologies, microbiology is likely to show attractive growth between 2017 and 2026. Microbiology technology is projected to reach nearly US$ 300 million revenue by 2026 end. It helps in identifying microorganisms for sepsis diagnosis and quantitative detection through culture media tests. Meanwhile, molecular diagnostics is also gaining traction in the market. Factors contributing to the growth of molecular diagnostics are accurate results and low turnaround time.
The report also profiles companies that are expected to remain active in the expansion of global sepsis diagnostics market through 2026, which include Abionic SA, Biomérieux SA, Siemens Healthineers, Thermo Fisher Scientific Inc., Quidel Corporation, Becton, Dickinson and Company, Luminex Corporation, Abbott Laboratories, Inc., Qiagen NV, T2 Biosystems, Inc., Roche Holdings AG (Roche Diagnostics Limited), and Danaher Corporation (Beckman Coulter, Inc.).
Ask Industry Expert about this Report - https://www.factmr.com/connectus/sample?flag=AE&rep_id=391
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.
11140 Rockville Pike
Rockville, MD 20852
Read Industry News at - https://www.industrynewsanalysis.com/